Research programme: TNF-alpha converting enzyme inhibitors - GlaxoSmithKline
Latest Information Update: 20 Mar 2007
At a glance
- Originator GlaxoSmithKline
- Class Small molecules
- Mechanism of Action Tumour necrosis factor-alpha convertase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 17 May 2002 Preclinical trials in Inflammation in USA (PO)